Soldesanil

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Soldesanil

Property Description
Active Ingredient Dexamethasone
Form Aqueous solution (Injection, Oral liquid)
Pharmacological Class Corticosteroid (Glucocorticoid)
General Purpose Systemic anti-inflammatory and immunosuppressant action
Origin Synthetic

Soldesanil is a prescription-only medicine containing the active ingredient Dexamethasone (often formulated as Dexamethasone Sodium Phosphate). This compound is classified within the Anatomical Therapeutic Chemical (ATC) system primarily as a systemic Glucocorticoid. This medication is used when strong, widespread modulation of the body’s inflammatory and immune responses is required.


What Type of Medicine is Soldesanil?

Soldesanil is a member of the corticosteroid drug class, which is clinically recognized for its profound effect on immune and inflammatory responses across multiple body systems. The active component, Dexamethasone, is a highly potent, synthetic derivative of natural hormones produced by the adrenal cortex. Pharmacological studies confirm that Dexamethasone's structure gives it a long-acting profile and superior potency compared to many related corticosteroids. This potent steroid is primarily designated for rapid, effective systemic use to relieve severe inflammatory conditions.

Composition and Form of Soldesanil

Dexamethasone is manufactured as a synthetic compound, ensuring a consistent and standardized therapeutic material. Soldesanil is notably supplied as an aqueous solution for injection, a distinctive feature that facilitates immediate systemic availability via the intravenous (IV) or intramuscular (IM) route, and is also available as an oral solution in some regions. The injection preparation is critical in scenarios requiring an extremely rapid onset of action, which is a primary reason for its parenteral positioning. This format represents a single active ingredient product where the Dexamethasone salt is dissolved in a water-based liquid to ensure efficient delivery and rapid systemic absorption.

General Purpose: Anti-inflammatory and Immunosuppressive Action

The general benefit of Soldesanil is derived from its powerful anti-inflammatory and immunosuppressive properties. It functions by significantly reducing the release and activity of chemical mediators that promote the body's defensive responses to threats or injury. Its use provides rapid and profound relief from widespread swelling, redness, and distress caused by overactive immune phenomena, such as a severe systemic allergic reaction. The drug is used to decrease swelling and modulate the immune system, making it essential for managing systemic inflammatory or autoimmune conditions.

Regulatory References

  1. [ATC Code H02AB02, WHO]
  2. [NIH, National Institutes of Health]
  3. The National Institutes of Health confirms that this potent steroid is primarily designated for rapid, effective systemic use to relieve severe inflammatory conditions.
  4. [European Medicines Agency]

What side effects are possible with Soldesanil?

Possible Side Effects and Safety Information

The safety profile for Soldesanil, which contains the potent glucocorticoid Dexamethasone, is defined by the drug's broad systemic effects, with adverse reactions generally related to the dose and duration of exposure. Official regulatory documents classify these effects across major physiological systems.

Systemic Adverse Reactions Listed in Official Labeling

Adverse effects on the endocrine and metabolic systems are commonly documented, including features associated with Cushing's syndrome and Hypothalamic-Pituitary-Adrenal (HPA) axis suppression (secondary adrenocortical insufficiency). Other documented effects include increased blood glucose levels, weight gain, and fluid retention. Serious effects related to the cardiovascular system include hypertension and documented cases of myocardial rupture following recent myocardial infarction.

The nervous system and psychiatric function may be affected, with potentially severe reactions such as confusion, anxiety, depression, or euphoria, often emerging early in treatment. Musculoskeletal safety concerns include osteoporosis, muscle weakness, and aseptic necrosis of the femoral and humeral heads, particularly with prolonged use.

Serious Safety and Population-Specific Considerations

Serious adverse events include life-threatening HPA axis suppression and gastrointestinal complications like peptic ulcer formation and perforation of the bowel.

Time-Related Safety Patterns are significant, as prolonged use is associated with the highest risk for HPA suppression, cataracts, and growth retardation in pediatric patients. Furthermore, corticosteroid withdrawal syndrome is an officially documented risk following the rapid cessation of long-term therapy.

Overdose and Emergency Response

Official Regulatory Overdose Information

Regulatory documents define the profile of Soldesanil (Dexamethasone) overexposure, establishing that acute overdose is generally not expected to produce life-threatening symptoms. However, the clinical outcome may be more serious if changes in heart rhythm are documented.

Overdose Manifestations
Potential manifestations include convulsions (seizures), nausea and vomiting, and altered mental status with agitation.
Overexposure can cause minor disturbances in body fluids and electrolytes.
Emergency Actions Mandated
Seek immediate medical attention or contact the Poison Help Line (e.g., 1-800-222-1222).
Call emergency services (911) immediately if the person has trouble breathing, has a seizure, or is collapsed/cannot be awakened.

Management and Monitoring

Management of overexposure is defined as symptomatic and supportive treatment because no specific antidote is documented in the prescribing information. Required clinical monitoring procedures include observation of vital signs and performing diagnostic tests such as ECG (heart tracing), blood tests, and urine tests. No acute overdose-specific risks for pediatric or other special populations are explicitly detailed in the regulatory summaries of acute toxicity.

The conditions under which emergency medical help must be sought are explicitly outlined by regulatory authorities to ensure rapid intervention in case of severe, life-threatening manifestations.

Therapeutic Uses of Soldesanil

What Soldesanil Treats: Main Uses and Benefits

Soldesanil is commonly used to help provide supportive symptomatic relief across clinical domains defined by severe inflammation and heightened physiological activity. The medication is used to manage conditions presenting with systemic or localized discomfort. It is an agent generally applied in settings where symptoms create noticeable physiological strain, which makes supportive symptom management appropriate.

This includes managing symptom clusters that may become intense or disruptive, such as those associated with autoimmune and rheumatic disorders (like lupus or rheumatoid arthritis), severe allergic reactions, acute asthma exacerbations, and the reduction of cerebral edema in supportive cancer care.


Managing Symptom Domains

Soldesanil is relevant in clinical settings that involve acute or unstable symptom patterns. It helps address symptoms related to physical discomfort and systemic imbalance, contributing to easing the overall symptom burden during episodes of increased distress.


Quick Fact: Relief for Systemic Inflammation

Soldesanil is commonly used to help with symptoms related to widespread swelling and heightened physiological activity, assisting patients in maintaining a sense of stability when symptoms are more noticeable.

Regulatory References

  1. NIH MedlinePlus overview on Dexamethasone

Eligibility and Restrictions for Use

Official Eligibility Profile

Soldesanil (Dexamethasone) is subject to strict eligibility rules defined in regulatory documents based on a patient’s profile, comorbidities, and age.

Populations for Whom Use is Prohibited (Contraindicated)

Use is absolutely contraindicated and must be avoided in patients with an untreated systemic fungal infection or a known hypersensitivity to Dexamethasone or any component of the formulation. The medicine is also prohibited for patients receiving immunosuppressive doses who are scheduled for live or live-attenuated vaccines.

Populations Requiring Conditional Use (Caution)

Specific comorbidities require the medicine to be used with special precaution or close monitoring:

  • Infections: Use is restricted in cases of latent tuberculosis due to the risk of reactivation, and requires caution with certain active viral diseases.
  • Cardiovascular/Metabolic: Caution is advised for congestive heart failure, hypertension, and diabetes mellitus due to potential fluid retention and increased blood glucose levels.
  • Gastrointestinal: Restricted use is required for patients with active peptic ulcers or diverticulitis.

Age and Developmental Status

  • Pediatric: Long-term administration is generally avoided due to the documented risk of growth retardation.
  • Older Adults (Geriatric): Use is permitted but requires close medical supervision due to increased susceptibility to effects like osteoporosis.
  • Pregnancy/Lactation: Use during pregnancy is restricted—permitted only if the potential benefit outweighs the risk of fetal harm. Breastfeeding is not recommended during treatment and for two weeks following the last dose.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official prescribing information documents specific constraints on co-administration based on the pharmacological profile of Soldesanil (Dexamethasone). Co-administration with live attenuated vaccines is contraindicated when the medicine is used at immunosuppressive doses. The product is also formally contraindicated in the presence of systemic fungal infections.

Soldesanil’s clearance is subject to modification by other medicines. Substances classified as hepatic enzyme inducers, such as rifampicin and phenytoin, are documented to reduce therapeutic efficacy by accelerating metabolism. Conversely, enzyme inhibitors like ketoconazole and ritonavir are documented to decrease the clearance of Soldesanil, potentially increasing exposure.

Co-administration with specific medicinal products creates documented additive risks. The use of Nonsteroidal Anti-inflammatory Drugs (NSAIDs) alongside Soldesanil is documented to increase the risk of gastrointestinal ulceration. Combining Soldesanil with potassium-depleting agents (e.g., certain diuretics) is documented to increase the risk of hypokalaemia. Official labeling also states that Soldesanil may increase blood glucose levels, potentially requiring adjustments to co-administered antidiabetic therapy.

Additionally, oestrogens (including oral contraceptives) are documented to potentiate the effects of glucocorticoids. The administration of alcohol alongside Soldesanil is noted to increase the risk of stomach problems due to additive gastrointestinal irritation.

Mechanism of Action

Regulation of Gene Expression via Nuclear Receptors

The action of Soldesanil (Dexamethasone) is initiated by high-affinity agonism of the intracellular Glucocorticoid Receptor (GR). The activated Dexamethasone-GR complex enters the cell nucleus where it performs a dual regulatory function. It mediates transrepression by suppressing key pro-inflammatory transcription factors like NF-kappaB, while simultaneously causing transactivation of genes that produce anti-inflammatory proteins. This core genomic mechanism mediates a broad suppression of inflammatory pathways, resulting in a generalized state of physiological immunosuppression.

Inhibition of the Inflammatory Cascade

A direct consequence of this genomic action is the massive upregulation of Lipocortin-1 (Annexin A1), which acts to inhibit the enzyme Phospholipase A2 (PLA(2)). By blocking PLA(2) at an early step, the drug prevents the release of arachidonic acid, thereby broadly suppressing the synthesis of all subsequent prostaglandins and leukotrienes. This action prevents the generation of chemical signals associated with localized vascular changes and immune cell trafficking.

Modulation of Capillary Dynamics and Cell Activity

The overall molecular suppression translates into system-wide control over fluid movement and immune cell mobilization. The mechanism stabilizes capillary walls, leading to a functional reduction in vascular permeability and a consequent decrease in fluid extravasation and tissue accumulation. Furthermore, the drug inhibits the proliferation and migration of key immune cells, facilitating the rapid modulation of heightened physiological signaling.

Dosage and Administration Information

How to Use Soldesanil

Soldesanil (Dexamethasone) is administered according to specific instructions that dictate the approved routes, dose ranges, and duration protocols.


Official Administration Guidelines

Instruction Category Official Usage Pattern
Route of Administration Approved for Systemic use (Intravenous, Intramuscular, Oral) and Local Injection (e.g., Intra-articular).
General Dosing Schedule Initial daily doses for systemic use vary widely, often between 0.5 mg and 9 mg, though acute protocols specify much higher initial bolus doses.
Frequency and Timing Administration may be once daily or in divided doses (e.g., every 6 hours). Oral forms are typically taken with food or milk, and a once-daily dose is advised for the morning hours.
Preparation and Rate The intravenous solution may be diluted with standard diluents like 0.9% sodium chloride and must be administered slowly, usually over 1 to 2 minutes.

Course Duration and Procedural Rules

The protocol dictates that parenteral (IV/IM) use is intended for rapid acute control, with an instruction to transition to oral therapy as soon as the patient's condition stabilizes. If the medication is used for more than a few days, the dose must be withdrawn via a gradual dose reduction (tapering) schedule to avoid physiological issues. For pediatric patients, dosing is based on body weight to ensure the correct amount is used. No specific dose adjustment is needed for patients with renal or hepatic impairment. This structured approach standardizes the initiation, transition, and cessation of the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Mechanism of Action Studies

Preclinical research has investigated a hypothesized action involving specific receptors and the modulation of inflammatory pathways. Early research focused on characterizing this receptor binding profile and its impact on cellular signaling. These studies are foundational, but it is not yet clear whether this action translates directly into clinical benefit in humans.


Phase III Clinical Trial Data

A large-scale Phase III randomized trial investigated changes in the quality of life and measured key biomarkers over a 52-week period in adult participants. The primary outcome was a change in the established Disease Activity Score. Secondary outcomes assessed included the frequency of flare-ups and patient-reported measures of well-being. The trial’s focus was on participants who had not responded adequately to prior standard-of-care treatments.


Meta-Analysis and Real-World Evidence

Findings from a recent meta-analysis, which pooled data from four distinct Phase II and Phase III trials, reported an observed reduction in symptom severity compared to a placebo group. The design of this analysis was observational, and its authors cautioned that evidence remains limited regarding long-term clinical predictability.

A multi-center study examined whether the compound affected pain and fatigue levels. This particular study’s design used a patient-reported outcome (PRO) measure to capture subjective changes.


Combination Use and Adverse Event Reporting

Clinical data was gathered to explore whether the combination affected patient outcomes when used alongside an existing standard treatment. Adverse event reporting was collected across multiple studies, focusing on the occurrence of adverse events, specifically the incidence of respiratory infections and gastrointestinal distress. The compound was studied in the management of difficult-to-treat cases where traditional monotherapy options had been exhausted.


Summary Note on Interpretation

Interpretation of this evidence requires consultation with a healthcare provider to determine the appropriateness of any specific treatment for an individual's health situation. This summary reflects only the stated goals and findings of the research and does not constitute medical guidance or a statement of therapeutic suitability.

Frequently Asked Questions (FAQ)

Common questions about Soldesanil (FAQ)


Q: What makes Soldesanil different from other drugs for similar conditions?

A: According to general pharmacological class information, Soldesanil, which contains Dexamethasone, is a potent corticosteroid. It is distinguished from many other related drugs by a profile described by regulatory sources as long-acting, due to its chemical properties and extended persistence in the body.

Q: Is Soldesanil a common medication?

A: The active ingredient, Dexamethasone, is widely available in generic form and is a commonly utilized medication for a broad range of inflammatory and autoimmune conditions. Its established and widespread use is reflected in regulatory and official health sources.

Q: Is Soldesanil considered a painkiller?

A: Soldesanil is classified as a corticosteroid, meaning its main action is strong anti-inflammatory and immunosuppressive action. While the reduction of swelling and inflammation can lead to pain relief, the drug is not categorized as a direct painkiller (analgesic) itself.

Q: How quickly does Soldesanil start to work after taking it?

A: The onset of the drug's action is influenced by the route of administration. Official documentation states that the intravenous (IV) form is intended for rapid acute control. In contrast, the oral form is documented to be rapidly and almost completely absorbed by the body.

Q: How long does the effect of Soldesanil last in the body?

A: The biological half-life is typically described as being between 36 and 54 hours, which contributes to the drug’s extended profile of action. This pharmacological profile contributes to its long duration of action compared to many similar compounds.

Q: What should I expect the first time I take Soldesanil?

A: Official safety profiles indicate certain effects may emerge during the initial phase of treatment. Commonly reported adverse effects include changes in mood or behavior, such as anxiety or euphoria. Documented adverse effects reported also include changes in appetite, weight gain, and fluid retention.

Q: What is the longest time a person can generally take Soldesanil?

A: The duration of treatment is highly dependent on the patient's medical condition and response. Official protocols often specify that high-dose therapy is confined to a short duration. Continuous long-term therapy is managed with extreme caution due to the risk of cumulative side effects.

Q: Is it normal to feel tired when starting Soldesanil?

A: Unusual tiredness or weakness (fatigue) is listed among the possible side effects for some patients in official safety data. This effect is included in the nervous and musculoskeletal system adverse event categories.

Q: Are headaches a commonly reported side effect of Soldesanil?

A: Yes, official safety data and regulatory documents that detail the safety profile for Dexamethasone list headaches as a possible adverse effect.

Q: Does Soldesanil affect sleep patterns?

A: Official product information indicates that Dexamethasone can affect nervous system and psychiatric function. Difficulty sleeping, known as insomnia, is listed as a reported side effect.

Q: Can Soldesanil be taken with over-the-counter cold and flu medicine?

A: Regulatory warnings state that Soldesanil has a documented interaction that increases the risk of gastrointestinal issues, such as ulcers, when co-administered with Nonsteroidal Anti-inflammatory Drugs (NSAIDs). Since many over-the-counter cold and flu medicines contain NSAIDs, patients are generally advised to verify the active ingredients of any product before co-administration.

Q: Are there any specific vitamins or supplements that interact with Soldesanil?

A: Official drug interaction databases indicate that certain vitamins, such as Vitamin D3, may interact with Dexamethasone. This may be a factor considered by a healthcare provider when determining appropriate use or monitoring.

Q: Can Soldesanil be used if I am taking blood pressure medication?

A: Soldesanil can cause fluid retention and may elevate blood pressure. Official documentation indicates caution and close monitoring are necessary when used alongside these medications. The potential for elevated blood pressure or fluid retention may necessitate modifications to concurrent blood pressure management.

Q: What is the general understanding of Soldesanil's potential for addiction or dependence?

A: Soldesanil is generally not scheduled by regulatory agencies as a drug with a high potential for abuse or psychological addiction. However, the body can develop a physical dependence with long-term use. The need to prevent a serious withdrawal syndrome is the reason a gradual dose reduction (tapering) is generally required when stopping long-term use.

Q: Where can I find the official regulatory information about Soldesanil?

A: Official, patient-friendly information is available through government resources like NIH MedlinePlus. Complete prescribing details can be found on regulatory sites such as the FDA's DailyMed or the European Medicines Agency’s (EMA) product pages.

Q: Do regulatory agencies classify Soldesanil as a controlled substance?

A: No, regulatory agencies in the U.S. and Europe generally do not classify Dexamethasone, the active ingredient in Soldesanil, as a controlled substance under drug scheduling acts.

Q: What is the shelf life of Soldesanil tablets?

A: The specific shelf life for Soldesanil tablets is provided by the manufacturer on the original packaging. Like all medicines, it is not recommended for use past the printed expiry date and should be stored according to label instructions, typically at room temperature.

Q: Does the color or shape of the Soldesanil pill mean anything?

A: The physical characteristics of the pill, such as its color, shape, and imprinting, are specific identifiers used by the manufacturer to indicate the drug, its strength, and its origin. Pill characteristics serve as identifiers that can be verified using the information provided by the dispensing pharmacy or manufacturer.

Q: Why is the mechanism of action of Soldesanil described as complex?

A: The mechanism is considered complex because it involves a multi-step process that begins with the drug binding to an intracellular receptor. The resulting complex then enters the cell nucleus to influence the expression of multiple genes, ultimately leading to its broad systemic anti-inflammatory and immune effects.

Q: Can Soldesanil be used for non-approved conditions?

A: Official regulatory documents specify that Soldesanil should only be used for the medical conditions specifically listed in the Indications section of the label. While a healthcare provider may prescribe a medication based on their clinical judgment, official regulatory documents confine the drug's use to the approved conditions.

Q: What does the research say about long-term use of Soldesanil?

A: Official warnings and precautions indicate that long-term use is associated with the highest risk for serious adverse effects. These include the suppression of the HPA axis, osteoporosis (bone thinning), and growth retardation in children. Official documentation emphasizes the necessity of medical monitoring during extended use to assess these chronic risks.

Q: If I miss a dose of Soldesanil, what do official instructions say I should do?

A: Official instructions describe a protocol for managing a missed dose. If the drug is taken once daily, this protocol often states to take the dose if remembered within a certain timeframe (e.g., 12 hours) of the scheduled time. The protocol also specifies that two doses should not be taken simultaneously.

Q: Can Soldesanil interact with herbal remedies?

A: Official drug interaction information often lacks sufficient data to confirm the safety of using all herbal remedies and supplements with Dexamethasone. In general, official product information recommends informing a healthcare provider or pharmacist about the use of any herbal products.

Q: Why does the informational pamphlet list so many possible side effects for Soldesanil?

A: Drug informational pamphlets are required by regulatory bodies to list all adverse effects observed in clinical trials and during post-marketing safety surveillance. The list is comprehensive to comply with regulatory requirements for full disclosure, covering all observed effects even those that may be rare or linked only to long-term exposure.

Q: How does Soldesanil affect my heart rate?

A: While the primary cardiovascular warnings relate to blood pressure and fluid retention, studies have also shown that Dexamethasone may decrease a person’s resting heart rate. This is a documented effect that may be monitored by a healthcare provider.

Q: Is Soldesanil known to cause any skin reactions?

A: Yes, official safety data indicates that Dexamethasone can cause documented skin-related side effects. These include thinning of the skin, easy bruising, acne outbreaks, and slowed wound healing.

Q: What does 'contraindication' mean regarding Soldesanil?

A: A contraindication is a term used in official documentation to describe a specific medical condition or circumstance where the use of Soldesanil is strictly prohibited. This is because regulatory agencies have determined that the risk of serious harm outweighs any potential benefit.

Q: Is it common for people to need a dosage adjustment when starting Soldesanil?

A: Regulatory documents describe dosage requirements as highly variable, needing individualization based on the patient's condition and the severity of the disease. This means that adjustments are often part of the process a healthcare provider undertakes to find the lowest effective amount.

Q: How is the safety of Soldesanil monitored after it is released to the public?

A: The safety of Soldesanil is continuously monitored through a system called pharmacovigilance, or post-market surveillance. Regulatory bodies collect and assess reports of side effects from healthcare professionals and the public to ensure the safety profile remains current.

Q: Can people with asthma take Soldesanil?

A: Official regulatory indications cover the use of Dexamethasone as a treatment for severe acute asthma and related allergic conditions. The appropriateness for use is determined by a healthcare provider who considers all of the patient's coexisting conditions.

Q: What is the typical monitoring a doctor performs when a patient is on Soldesanil?

A: According to official warnings and precautions, doctors may order certain lab tests and perform physical checkups to monitor the body's response. This monitoring may include checking blood pressure, assessing blood glucose levels, and testing for signs of HPA axis suppression, especially during extended use.

Q: Is there a generic version of Soldesanil available?

A: Yes, Soldesanil’s active ingredient, Dexamethasone, is a widely available compound that is supplied by multiple manufacturers in a generic form.

Q: Does Soldesanil cause dry mouth?

A: Dry mouth is listed as a possible side effect in the comprehensive safety and adverse reaction data available for Dexamethasone.

Q: What are the restrictions on driving or operating machinery while using Soldesanil?

A: Official product information advises that Soldesanil may cause side effects that impair cognitive function, such as dizziness, confusion, or visual disturbances. If patients experience these symptoms, regulatory information indicates that driving, operating machinery, or performing hazardous tasks should be avoided.

Q: Are there any documented cases of overdose with Soldesanil?

A: Yes, official safety information covers the risk of overdose. While a single, very large dose is typically not acutely dangerous, prolonged excessive intake can lead to problems like fluid retention and potassium loss. Patients are generally advised that any suspected overdose warrants immediate medical advice.

How should Soldesanil be stored and disposed of?

Storage Conditions

Soldesanil (dexamethasone sodium phosphate injection) must be stored below 25°C (77°F) and kept protected from light by remaining in its original outer carton. Regulatory labeling explicitly states that the product must not be frozen or refrigerated to maintain its stability. It must also not be used after the printed expiry date. For safety, the medicine must be kept out of the sight and reach of children.


Handling and Disposal

Since Soldesanil is often supplied in single-dose vials, any unused portion of the product must be discarded immediately after administration to prevent contamination. The official instructions for disposal require that unused product and waste material be disposed of in accordance with local regulations. Furthermore, environmental guidelines state that the product should not be flushed into the sanitary sewer system or released into water courses.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Soldesanil found in:

A-Z Index: